Aprea Therapeutics (APRE) Stock Price, Quote, News & History | Benzinga

Aprea Therapeutics (APRE) Stock Price, Quote, News & History

APRENASDAQ

Logo brought to you by Benzinga Data

Trade with Public

Trade with Public

$0.8051

0.00911.14%

Last update: Feb 2, 12:35 PM

Overview

News Earnings Analyst Ratings Insider Trades Short Interest Stock Report

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$0.75

Close

-

Volume / Avg.

1.80M / 1.90M

Day Range

$0.67 - $0.88

52 Wk Range

0.55 - 4.65

Market Cap

$5.63M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

0.56%

Days to Cover

1

Recent Aprea Therapeutics Inc News

Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?

FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund clinical development and ensure company sustainability until 2026.

Vandana Singh

Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Lisa Levin

Why Aprea Therapeutics Shares Hit A New 52-Week Low Today

Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading lower by 17.59% to $5.20 after the company announced pricing of a $5.5 million underwritten public offering of common stock. What Else?

Henry Khederian

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-13.44M

Investing Cash Flow (TTM)

0

Financing Cash Flow (TTM)

933.07K

Free Cash Flow (TTM)

-13.44M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-12.51M

Analyst Trends and Forecast

1

Dec 25

1

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$8.17M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

0.51

Earnings Yield % (TTM)

-267.34%

Earnings Yield % (FWD)

-166.46%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.56

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$13.72M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$0.75

Close

-

Volume / Avg.

1.80M / 1.90M

Day Range

$0.67 - $0.88

52 Wk Range

0.55 - 4.65

Market Cap

$5.63M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

0.56%

Days to Cover

1

About

Sector

Health Care

Industry

Biotechnology

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for sol...

Show More

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Aprea Therapeutics (APRE) stock?

A

You can purchase shares of Aprea Therapeutics (NASDAQ:APRE) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Aprea Therapeutics (APRE) competitors?

A

Other companies in Aprea Therapeutics’s space includes: Immuron Ltd (NASDAQ:IMRN), Dermata Therapeutics Inc (NASDAQ:DRMA), Acurx Pharmaceuticals Inc (NASDAQ:ACXP), Can Fite Biopharma Ltd (AMEX:CANF) and Geovax Labs Inc (NASDAQ:GOVX).

Q

What is the forecast, or price target, for Aprea Therapeutics (APRE) stock?

A

Aprea Therapeutics has a consensus price target of $10.33.

Q

What is the current price for Aprea Therapeutics (APRE)?

A

The stock price for Aprea Therapeutics (NASDAQ: APRE) is $0.8051 last updated February 2, 2026 at 12:35 PM EST.

Q

Does Aprea Therapeutics (APRE) pay a dividend?

A

There are no upcoming dividends for Aprea Therapeutics.

Q

When is Aprea Therapeutics (NASDAQ:APRE) reporting earnings?

A

Aprea Therapeutics does not have any upcoming earnings scheduled.

Q

Is Aprea Therapeutics (APRE) going to split?

A

There is no upcoming split for Aprea Therapeutics.

Q

What sector and industry does Aprea Therapeutics (APRE) operate in?

A

Aprea Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Dermata Therapeutics Inc

Acurx Pharmaceuticals Inc

Can Fite Biopharma Ltd

Geovax Labs Inc

Abpro Holdings Inc

Indaptus Therapeutics Inc